An Automated Micro‐Immunobeads‐Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease

Abstract The anticipated rise in the prevalence of Alzheimer's disease (AD) under global demographic shifts necessitates the development of universally accessible screening and diagnostic tools, of which blood tests hold the promise. However, the widespread adoption of blood tests remains impeded by the lack of analytically validated biomarkers and accessible decentralized platforms. Here, the study presents a portable and automated micro‐immunobeads‐based electromagnetic operation system, termed MEMOs, targeting potential AD blood biomarker exosome‐bound Aβ42 (Exo‐Aβ42), for automated blood testing of AD. MEMOs integrates a microfluidic exosome‐detection biological chip (μ‐Exo Biochip) embedded with a magnetic field‐responsive assay for detecting Exo‐Aβ42 and a microbead operation electromagnetic chip (μ‐Bead EMchip) for programmable and addressable actuation, collectively delivering a high level of accurate and automated AD testing. In both animal and clinical samples, the levels of Exo‐Aβ42 measured using MEMOs have shown significant correlations with various progressive stages of AD. With the features of cost‐effective manufacturing, minimized hands‐on time, and an easy operation workflow, MEMOs offers an accessible pathway toward diagnosing and monitoring the progression of AD in decentralized practice.